MET and adenocarcinoma: Among the cases of adenocarcinoma, the details of the detected driver alterations of the ODxTT are as follows: EGFR Ex.19 deletion (n = 22, 15.9%), EGFR Ex.21 L858R (n = 29, 21.0%), EGFR Ex.20 insertion (n = 3, 2.2%), EGFR uncommon/compound mutations (n = 4, 2.9%), KRAS G12C mutation (n = 7, 5.1%), other KRAS mutations (n = 18, 13.0%), MET Ex.14 skipping (n = 5, 3.6%), ERBB2 Ex.20 insertion (n = 5, 3.6%), ALK fusion (n = 4, 2.9%), and BRAF V600E mutation (n = 3, 2.2%).